STOCK TITAN
  1. Home
  2. Sec-filings
  3. TXG
  4. [Form 4] 10x Genomics, Inc. Insider Trading Activity

10x Genomics (NASDAQ: TXG) director sells under 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

10x Genomics, Inc. director Sarah A. Teichmann reported two open-market sales of Class A Common Stock of TXG. On August 13, 2026 she sold 5,278 shares at $57.29 per share, and on August 14, 2026 she sold 2,273 shares at $57.15 per share, for total reported sales of 7,551 shares. Both transactions were effected pursuant to her Rule 10b5-1 trading plan adopted on May 14, 2026.

Positive

  • None.

Negative

  • None.
Insider Teichmann Sarah A.
Role Director
Sold 7,551 shs ($432K)
Type Security Shares Price Value
Sale Class A Common Stock F1 2,273 $57.15 $130K
Sale Class A Common Stock F1 5,278 $57.29 $302K
Holdings After Transaction: Class A Common Stock — 28,058 shares (Direct)
Footnotes (1)
  1. F1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 14, 2026.
Shares sold on 2026-08-13 5,278 shares Class A Common Stock sale at $57.29 per share
Shares sold on 2026-08-14 2,273 shares Class A Common Stock sale at $57.15 per share
Total shares sold 7,551 shares Net reported sales across both transactions
Price per share 2026-08-13 $57.29 Sale price for 5,278 Class A shares
Price per share 2026-08-14 $57.15 Sale price for 2,273 Class A shares
Rule 10b5-1 trading plan regulatory
"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open market or private transaction financial
"transaction_code_description: Sale in open market or private transaction"
Class A Common Stock financial
"security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

What insider transactions did TXG director Sarah A. Teichmann report?
Sarah A. Teichmann reported two sales of 10x Genomics (TXG) Class A Common Stock, totaling 7,551 shares, executed on August 13 and 14, 2026 under a Rule 10b5-1 trading plan.

How many TXG shares did Sarah A. Teichmann sell on August 13, 2026?
On August 13, 2026, Sarah A. Teichmann sold 5,278 TXG Class A shares at a price of $57.29 per share in an open-market or private transaction reported on Form 4.

How many TXG shares did Sarah A. Teichmann sell on August 14, 2026?
On August 14, 2026, Sarah A. Teichmann sold 2,273 TXG Class A shares at a price of $57.15 per share in a reported open-market or private transaction.

Were Sarah A. Teichmann’s TXG share sales made under a Rule 10b5-1 plan?
Yes, both reported TXG share sales were effected under Sarah A. Teichmann’s Rule 10b5-1 trading plan, which the disclosure states was adopted on May 14, 2026.

What is the total number of TXG shares sold in this Form 4 by Sarah A. Teichmann?
Across the two reported transactions, Sarah A. Teichmann sold a total of 7,551 shares of 10x Genomics (TXG) Class A Common Stock, according to the Form 4 summary data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Teichmann Sarah A.
(Last)(First)(Middle)
C/O 10X GENOMICS, INC.
6230 STONERIDGE MALL ROAD
(Street)
PLEASANTON CALIFORNIA 94588
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock08/13/2026S(1)5,278D$57.2930,331D
Class A Common Stock08/14/2026S(1)2,273D$57.1528,058D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 14, 2026.
/s/ Randy Wu, as Attorney-in-Fact for Sarah A. Teichmann08/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR